Blog - Litchlab

EN

CN

{$ImageUrl,alt}

Blog

Home>Blog

Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine Delivery

Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine DeliveryLiposomes, as crucial carriers for vaccine delivery, possess unique structural and functional characteristics that enable them to meet the complex needs of various vaccines. Fr...

Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma

Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma In May 2024, the U.S. Food and Drug Administration (FDA) announced the approval of irinotecan lipos...

mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development

mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development Driven by the COVID-19 pandemic, mRNA vaccines and lipid nanoparticle (LNP) delivery systems have become key technologies i...

Litchlab Launches SynerLipo™ Platform to Accelerate Co-Loaded Liposomal Oncology Therapeutics and Global CDMO Engagements

Litchlab, an innovation-focused contract development and manufacturing organization (CDMO) specializing in complex drug delivery systems, has officially launched its next-generation liposome platform — SynerLipo™. Engineered for dual-drug co-encapsulation, coo...

Litchlab Launches LiLinker™ Platform to Advance ADC Linker Design, Process Integration, and Global-Ready Bioconjugation Solutions

As Antibody-Drug Conjugates (ADCs) continue to reshape the oncology therapeutic landscape, Litchlab officially announces the launch of LiLinker™, a dedicated linker development and CDMO platform designed to bridge molecular design with process-ready impl...

Litchlab Expands ADC CDMO Services: Building an Integrated Platform for High-Potency Bioconjugate Drug Development

With Antibody-Drug Conjugates (ADCs) becoming a cornerstone of targeted oncology therapies worldwide, Litchlab today announced the full deployment of its end-to-end ADC development and CDMO service platform. Leveraging its deep expertise in high-potency drug d...

Litchlab Advances PEGylated Liposome Platform to Drive Long-Circulating Nanomedicine Development and Global CDMO Solutions

Litchlab, a leading CDMO innovator in nanoparticle-based drug delivery, has announced a significant enhancement of its PEGylated liposome (PEG-liposome) platform. This next-generation system focuses on long-circulating delivery, enhanced pharmacokinetics...

Litchlab Empowers Dual-Drug Liposomal Delivery: A CDMO Engine for Next-Gen Combination Therapies

As the global pharmaceutical industry increasingly pivots toward multi-target interventions and combination strategies, dual-drug co-encapsulated liposomes are emerging as a transformative solution to overcome the limitations of monotherapies. Leveraging a dec...

Litchlab Advances Actively Targeted Liposome Drug Delivery for Precision Oncology and Beyond

Litchlab, a global provider of next-generation nanomedicine delivery platforms, is accelerating the advancement of its Actively Targeted Liposome (ATL) technology to address the growing demand for precision drug delivery in oncology and other complex therapeut...

上一页 1 2 3 4 5 下一页